Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34889425)

  • 21. The clinical significance of molecular response in indolent follicular lymphomas.
    López-Guillermo A; Cabanillas F; McLaughlin P; Smith T; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Pugh W; Lee MS
    Blood; 1998 Apr; 91(8):2955-60. PubMed ID: 9531606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.
    Grimaldi D; Genuardi E; Ferrante M; Ferrero S; Ladetto M
    Curr Treat Options Oncol; 2018 Nov; 19(12):71. PubMed ID: 30402764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD
    Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
    Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
    J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurable Residual Disease Monitoring in Lymphoma.
    Cuzzo B; Lipsky A; Cherng HJ
    Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
    Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
    J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.
    Sabesan V; Cairo MS; Lones MA; Perkins SL; Morris E; Sposto R; Van De Ven C; Shiramizu B
    J Pediatr Hematol Oncol; 2003 Feb; 25(2):109-13. PubMed ID: 12571460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
    Zwicky CS; Maddocks AB; Andersen N; Gribben JG
    Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
    Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
    Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
    Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C
    J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
    Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
    Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
    Herrera AF; Armand P
    J Clin Oncol; 2017 Dec; 35(34):3877-3887. PubMed ID: 28933999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
    Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C
    Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.